Rebordosa C, Houben E, Laugesen K, Bothner U, Montonen J, Aguado J, Overbeek JA, Ehrenstein V, Asmar J, Wallace L, Gilsenan AW. No evidence of off-label use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: a drug utilization study. Sci Rep. 2020 Jan 17;10(1):586. doi: 10.1038/s41598-019-57397-5
Ritchey ME, Hollis KA, Hauber AB, Gilsenan A, Krueger WS. Reporting of "Benefit-Risk" studies for medical devices in published literature. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S175. doi: 10.1016/j.jval.2018.04.1167
Zhou X, Radigue C, Allshouse AA, Gilsenan A. In Europe, how representative are overweight/obese subjects recruited via the internet? Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A326.
Gilsenan AW. Development of a minimum dataset (MDS)-based comorbidity index for a nursing home population. Poster presented at the Fourth International Society for Pharmacoeconomics and Outcomes Research Congress; 2001. [abstract] Value Health. 2001 Sep; 4(6):417-8.